سعر اونكودوكس 10 مجم فيال 2022

Oncodox: doxorubicin 10 mg vial for intravenous use (Cipla); anthracycline cytotoxic chemotherapy.

• Adjuvant multi-agent chemotherapy for node-positive breast cancer after resectionPopulation: Adult womenDailyMed (U.S. National Library of Medicine)
• ALL, AML, Hodgkin and non-Hodgkin lymphoma, and metastatic breast, Wilms, neuroblastoma, soft tissue and bone sarcoma, ovarian, bladder, thyroid, gastric and bronchogenic carcinomaDailyMed (U.S. National Library of Medicine)

• Most common (>10%): alopecia, nausea and vomiting; also cardiomyopathy, myelosuppression, secondary malignancies.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Severe myocardial insufficiency; recent myocardial infarction (4-6 weeks); severe persistent drug-induced myelosuppression; severe hepatic impairment; severe hypersensitivity to doxorubicin.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: cumulative dose-related cardiomyopathy (1-20% at 300-500 mg/m2); secondary AML/MDS; extravasation and tissue necrosis; severe myelosuppression.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Tumour lysis syndrome; radiation sensitisation and recall; embryo-fetal toxicity.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• CYP3A4, CYP2D6 and/or P-gp inhibitors and inducersAvoid concomitant use.DailyMed (U.S. National Library of Medicine)
• TrastuzumabDo not combine: increased risk of cardiac dysfunction.DailyMed (U.S. National Library of Medicine)

• Can cause fetal harm; avoid during the first trimester; teratogenic and embryotoxic in animals. Effective contraception advised for females and males.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Present in human milk (peak 4.4-fold plasma level); do not breastfeed during treatment and for 10 days after the final dose.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Doxorubicin: Intercalates DNA and inhibits topoisomerase II, disrupting DNA replication and transcription.